* Elicio Therapeutics Inc ELTX.OQ reported a quarterly
adjusted
loss of 64 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-2.44. The mean expectation of two analysts
for the quarter was for a loss of 96 cents per share. Wall
Street expected results to range from $-1.04 to -88 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Elicio Therapeutics Inc's reported EPS for the quarter was
a
loss of 64 cents.
* The company reported a quarterly loss of $7.23 million.
* Elicio Therapeutics Inc shares had risen by 5.1% this
quarter and lost 48.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Elicio
Therapeutics Inc is $10.00
This summary was machine generated from LSEG data August 13 at
09:49 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.96 -0.64 Beat
Mar. 31 2024 -1.09 -1.15 Missed
Dec. 31 2023 -0.78 -1.75 Missed
Sep. 30 2023 -0.80 -1.27 Missed